Impact of cyp51A mutations on the pharmacokinetic and pharmacodynamic properties of voriconazole in a murine model of disseminated aspergillosis

Antimicrobial Agents and Chemotherapy

Volumn 54, Issue 11, 2010, Pages 4758-4764

  Mavridou, Eleftheria ^a,b   Bruggemann, Roger J M ^a,b   Melchers, Willem J G ^a,b   Verweij, Paul E ^a,b   Mouton, Johan W ^a,b  

^a RADBOUD UNIVERSITY MEDICAL CENTER   (Netherlands)

^b CANISIUS WILHELMINA HOSPITAL   (Netherlands)

Author keywords

[No Author keywords available]

Indexed keywords

AMPHOTERICIN; CASPOFUNGIN; ITRACONAZOLE; POSACONAZOLE; STEROL 14ALPHA DEMETHYLASE; VORICONAZOLE;

ANIMAL EXPERIMENT; ANIMAL MODEL; ANTIFUNGAL SUSCEPTIBILITY; AREA UNDER THE CURVE; ARTICLE; ASPERGILLUS FUMIGATUS; CONTROLLED STUDY; DOSE RESPONSE; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG DOSE COMPARISON; DRUG EFFICACY; DRUG HALF LIFE; FEMALE; GENE MUTATION; IN VITRO STUDY; IN VIVO STUDY; INVASIVE ASPERGILLOSIS; MAXIMUM PLASMA CONCENTRATION; MINIMUM INHIBITORY CONCENTRATION; MOUSE; NONHUMAN; PHARMACODYNAMICS; PHARMACOGENETICS; PHARMACOKINETICS; PRIORITY JOURNAL; SURVIVAL; TIME TO MAXIMUM PLASMA CONCENTRATION; WILD TYPE;

ADMINISTRATION, ORAL; ANIMALS; ANTIFUNGAL AGENTS; ASPERGILLOSIS; ASPERGILLUS FUMIGATUS; CYTOCHROME P-450 ENZYME SYSTEM; FEMALE; FUNGAL PROTEINS; MICE; MICROBIAL SENSITIVITY TESTS; MUTATION; PYRIMIDINES; TRIAZOLES;

EID: 78049299102     PISSN: 00664804     EISSN: 10986596     Source Type: Journal    
DOI: 10.1128/AAC.00606-10     Document Type: Article

References (28)

1. Andes, D., K. Marchillo, T. Stamstad, and R. Conklin. 2003. In vivo pharmacokinetics and pharmacodynamics of a new triazole, voriconazole, in a murine candidiasis model. Antimicrob. Agents Chemother. 47:3165-3169.
2. Arendrup, M. C., E. Mavridou, K. L. Mortensen, E. Snelders, N. Frimodt-Møller, H. Khan, W. J. G. Melchers, and P. E. Verweij. 2010. Development of azole resistance in Aspergillus fumigatus during azole therapy associated with change in virulence. PLoS One 5:e10080.
3. Bruggemann, R. J., N. M. Blijlevens, D. M. Burger, B. Franke, P. F. Troke, and J. P. Donnelly. 2010. Pharmacokinetics and safety of 14 days intravenous voriconazole in allogeneic haematopoietic stem cell transplant recipients. J. Antimicrob. Chemother. 65:107-113.
4. Brüggemann, R. J., D. J. Touw, R. E. Aarnoutse, P. E. Verweij, and D. M. Burger. 2009. International interlaboratory proficiency testing program for measurement of azole antifungal plasma concentrations. Antimicrob. Agents Chemother. 53:303-305.
5. Craig, W. A. 1998. Pharmacokinetic/pharmacodynamic parameters: rationale for antibacterial dosing of mice and men. Clin. Infect. Dis. 26:1.
6. Forrest, A., C. H. Ballow, D. E. Nix, M. C. Birmingham, and J. J. Schentag. 1993. Development of a population pharmacokinetic model and optimal sampling strategies for intravenous ciprofloxacin. Antimicrob. Agents Chemother. 37:1065-1072.
7. Graybill, J. R., L. K. Najvar, G. M. Gonzalez, S. Hernandez, and R. Bocanegra. 2003. Improving the mouse model for studying the efficacy of voriconazole. J. Antimicrob. Chemother. 51:1373-1376.
8. Howard, S. J., D. Cerar, M. J. Anderson, and A. Albarrag. 2009. Frequency and evolution of azole resistance in Aspergillus fumigatus associated with treatment failure. Emerg. Infect. Dis. 15:1068-1076.
9. MacCallum, D. M., and F. C. Odds. 2002. Influence of grapefruit juice on itraconazole plasma levels in mice and guinea pigs. J. Antimicrob. Chemother. 50:219.
10. Mann, P. A., R. M. Parmegiani, S. Q. Wei, C. A. Mendrick, X. Li, D. Loebenberg, B. DiDomenico, R. S. Hare, S. S. Walker, and P. M. McNicholas. 2003. Mutations in Aspergillus fumigatus resulting in reduced susceptibility to posaconazole appear to be restricted to a single amino acid in the cytochrome P450 14alpha-demethylase. Antimicrob. Agents Chemother. 47:577-581.
11. Mavridou, E., R. J. Bruggemann, W. J. Melchers, J. W. Mouton, and P. E. Verweij. 2010. Efficacy of posaconazole against three clinical Aspergillus fumigatus isolates with mutations in the cyp51A gene. Antimicrob. Agents Chemother. 54:860-865.
12. Mellado, E., G. Garcia-Effron, L. Alcazar-Fuoli, M. Cuenca-Estrella, and J. L. Rodriguez-Tudela. 2004. Substitutions at methionine 220 in the 14alpha-sterol demethylase (Cyp51A) of Aspergillus fumigatus are responsible for resistance in vitro to azole antifungal drugs. Antimicrob. Agents Chemother. 48:2747-2750.
13. Mellado, E., G. Garcia-Effron, L. Alcázar-Fuoli, W. J. Melchers, P. E. Verweij, M. Cuenca-Estrella, and J. L. Rodríguez-Tudela. 2007. A new Aspergillus fumigatus resistance mechanism conferring in vitro cross-resistance to azole antifungals involves a combination of cyp51A alterations. Antimicrob. Agents Chemother. 51:1897-1904.
14. Nascimento, A. M., G. H. Goldman, S. Park, S. A. Marras, G. Delmas, U. Oza, K. Lolans, M. N. Dudley, P. A. Mann, and D. S. Perlin. 2003. Multiple resistance mechanisms among Aspergillus fumigatus mutants with high-level resistance to itraconazole. Antimicrob. Agents Chemother. 47:1719-1726.
15. Pfaller, M. A., and National Committee for Clinical Laboratory Standards. 1998. Reference method for broth dilution antifungal susceptibility testing of conidium-forming filamentous fungi: proposed standard. National Committee for Clinical Laboratory Standards, Wayne, PA.
16. Purkins, L., N. Wood, P. Ghahramani, K. Greenhalgh, M. J. Allen, and D. Kleinermans. 2002. Pharmacokinetics and safety of voriconazole following intravenous- to oral-dose escalation regimens. Antimicrob. Agents Chemother. 46:2546-2553.
17. Purkins, L., N. Wood, K. Greenhalgh, M. J. Allen, and S. D. Oliver. 2003. Voriconazole, a novel wide-spectrum triazole: oral pharmacokinetics and safety. Br. J. Clin. Pharmacol. 56:10-16.
18. Rodriguez-Tudela, J. L., B. Almirante, D. Rodriguez-Pardo, F. Laguna, J. P. Donnelly, J. W. Mouton, A. Pahissa, and M. Cuenca-Estrella. 2007. Correlation of the MIC and dose/MIC ratio of fluconazole to the therapeutic response of patients with mucosal candidiasis and candidemia. Antimicrob. Agents Chemother. 51:3599-3604.
19. Roffey, S. J., S. Cole, P. Comby, D. Gibson, S. G. Jezequel, A. N. R. Nedderman, D. A. Smith, D. K. Walker, and N. Wood. 2003. The disposition of voriconazole in mouse, rat, rabbit, guinea pig, dog, and human drug metabolism and disposition: the biological fate of chemicals. Drug Metab. Dispos. 31:731-741.
20. Snelders, E., H. A. van der Lee, J. Kuijpers, A. J. Rijs, J. Varga, R. A. Samson, E. Mellado, A. R. Donders, W. J. Melchers, and P. E. Verweij. 2008. Emergence of azole resistance in Aspergillus fumigatus and spread of a single resistance mechanism. PLoS Med. 5:e219.
21. Sugar, A. M., and X. P. Liu. 2001. Efficacy of voriconazole in treatment of murine pulmonary blastomycosis. Antimicrob. Agents Chemother. 45:601-604.
22. Upton, A., K. A. Kirby, P. Carpenter, M. Boeckh, and K. A. Marr. 2007. Invasive aspergillosis following hematopoietic cell transplantation: outcomes and prognostic factors associated with mortality. Clin. Infect. Dis. 44:531-540.
23. Van Der Linden, J. W. M., W. J. G. Melchers, P. E. Verweij, R. R. Jansen, C. E. Visser, S. E. Geerlings, D. Bresters, and E. J. Kuijper. 2009. Azole-resistant central nervous system aspergillosis. Clin. Infect. Dis. 48:1111-1113.
24. van Leer-Buter, C., R. P. Takes, K. M. Hebeda, W. J. Melchers, and P. E. Verweij. 2007. Aspergillosis - and a misleading sensitivity result. Lancet 370:102.
25. Veronese, M. L., L. P. Gillen, J. P. Burke, E. P. Dorval, W. W. Hauck, E. Pequignot, S. A. Waldman, and H. E. Greenberg. 2003. Exposure-dependent inhibition of intestinal and hepatic CYP3A4 in vivo by grapefruit juice. J. Clin. Pharmacol. 43:831-839.
26. Verweij, P. E., S. J. Howard, W. J. Melchers, and D. W. Denning. 2009. Azole-resistance in Aspergillus: proposed nomenclature and breakpoints. Drug Resist. Updat. 12:141-147.
27. Verweij, P. E., E. Mellado, and W. J. Melchers. 2007. Multiple-triazole-resistant aspergillosis. N. Engl. J. Med. 356:1481-1483.
28. Walsh, T., E. Anaissie, D. Denning, R. Herbrecht, D. Kontoyiannis, K. Marr, V. Morrison, B. Segal, W. Steinbach, D. Stevens, J.-A. Burik, J. Wingard, and T. Patterson. 2008. Treatment of aspergillosis: clinical practice guidelines of the Infectious Diseases Society of America. Clin. Infect. Dis. 46:327-360.